We are live on ! Find out more
BCM

Bronte Capital Management Portfolio holdings

AUM $1.01B
1-Year Est. Return 47.99%
This Fund
S&P 500
This Quarter Est. Return
+7.37%
1 Year Est. Return
+47.99%
3 Year Est. Return
+112.22%
5 Year Est. Return
+138.3%
10 Year Est. Return
AUM
$1.52B
AUM Growth
+$149M
Cap. Flow
+$202M
Cap. Flow %
13.36%
Top 10 Hldgs %
87.35%
Holding
30
New
3
Increased
10
Reduced
15
Closed
1

Sector Composition

Rank Sector Weight
1 Financials 18.89%
2 Communication Services 10.45%
3 Consumer Staples 10.21%
4 Healthcare 6.35%
5 Materials 3.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MACK
26
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$2.1M 0.14%
537,584
-11,252
-2% -$48.8K
BNTX icon
27
BioNTech
BNTX
$22.9B
$1.73M 0.11%
6,702
-93
-1% -$25.5K
BYND icon
28
Beyond Meat
BYND
$292M
$969K 0.06%
+14,873
New +$1.27M
DBTX
29
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$731K 0.05%
157,216
-2,246
-1% -$15.5K
VIR icon
30
Vir Biotechnology
VIR
$1.46B
-74,920
Closed -$3.26M

Similar funds

Bronte Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Bronte Capital Management held 30 positions worth $1.52B, up 11% from $1.37B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Bronte Capital Management deployed $202M of net new capital in Q4 2021, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 75,627 shares worth $3.81M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 19% a quarter earlier, followed by Communication Services and Consumer Staples.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $3.39M trimmed.

  • Bronte Capital Management's largest Q4 2021 buy was Sociedad Química y Minera de Chile: 75,627 shares worth $3.81M.
  • Bronte Capital Management added most to Herbalife in Q4 2021, an estimated $17.1M increase.
  • Bronte Capital Management's biggest Q4 2021 reduction was Alphabet (Google) Class C, cutting an estimated $3.39M.
  • Bronte Capital Management fully exited Vir Biotechnology in Q4 2021, selling an estimated $3.26M.
  • Bronte Capital Management's ten largest holdings make up 87% of its $1.52B portfolio in Q4 2021.
  • Bronte Capital Management opened 3 new positions and closed 1 in Q4 2021.
  • Bronte Capital Management's portfolio value rose 11% quarter-over-quarter to $1.52B.

Based on Bronte Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.